Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

Phase 1CT-202Positive

AI Analysis

Context Therapeutics announced the first patient has been dosed in a Phase 1 trial of CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody.

Phase

Phase 1

First patient dosed

Importance:5/10

Sentiment:

0.30

Phase 1Clinical TrialBispecific AntibodyT cell engagingNectin-4CD3

Related Companies

Read the original article

Published by GlobeNewswire Clinical Studies on September 9, 2026 11:30 AM